Quantitation of Plasma Proteins to Predict Taxane-Induced Peripheral Neuropathy
JCO Precision Oncology · 2025
DOI: 10.1200/po-24-00380 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Nam Nguyen-Hoang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI. Hauptthemen laut MEDLINE: Peripheral Nervous System Diseases, Paclitaxel, Breast Neoplasms, Blood Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Taxane-induced peripheral neuropathy (TIPN) is a dose-limiting toxicity of paclitaxel in patients with cancer. TIPN prediction is challenging although patients with higher systemic paclitaxel exposure have higher TIPN risk. This study aimed to identify protein predictors of TIPN and paclitaxel pharmacokinetics (PK). METHODS This is a retrospective analysis of a prospective study of females with early-stage breast cancer receiving weekly paclitaxel. TIPN was assessed using the sensory subscale of the European Organisation for Research and Treatment of Cancer QLQ-Chemotherapy-Induced Peripheral Neuropathy (CIPN)20 (CIPN8). A blood sample was collected within 10 minutes before the end of the first paclitaxel infusion to measure plasma proteins using liquid chromatography-mass spectrometry and to estimate maximum systemic paclitaxel concentration ( C max ). A second sample was collected approximately 24 hours after the first infusion to estimate paclitaxel time above threshold ( T c >0.05 ). Linear mixed-effect and regression models were used to identify proteins predictive of TIPN and paclitaxel PK parameters, respectively, using a Bonferroni-adjusted α = .0006. RESULTS Data from 36 participants were included in the analysis testing associations of 83 proteins with TIPN or PK. Higher levels of complement C3 were associated with more severe TIPN trajectories ( P = .0002). No proteins were associated with either C max or T c >0.05 (all P > .0006). CONCLUSION Complement C3 concentration at the end of initial paclitaxel infusion may be useful for identifying patients with breast cancer and potentially other tumor types who could benefit from TIPN prevention strategies to improve long-term treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI.
- Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI.
- Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI.
ORCID-Profile: Nam Nguyen-Hoang, Yaping Liu, N Lynn Henry, Manjunath P Pai, Hao-Jie Zhu, Daniel L Hertz
Förderung
- NCATS NIH HHS
- NCI NIH HHS
Zitieren
APA
Nguyen-Hoang, N., Liu, Y., Henry, N. L., Pai, M. P., Zhu, H. J., & Hertz, D. L. (2025). Quantitation of Plasma Proteins to Predict Taxane-Induced Peripheral Neuropathy. JCO Precision Oncology. https://doi.org/10.1200/po-24-00380
Vancouver
Nguyen-Hoang N, Liu Y, Henry NL, Pai MP, Zhu HJ, Hertz DL. Quantitation of Plasma Proteins to Predict Taxane-Induced Peripheral Neuropathy. JCO Precision Oncology. 2025. doi:10.1200/po-24-00380
BibTeX
@article{NguyenHoang2025,
author = {Nguyen-Hoang, Nam and Liu, Yaping and Henry, N Lynn and Pai, Manjunath P and Zhu, Hao-Jie and Hertz, Daniel L},
title = {Quantitation of Plasma Proteins to Predict Taxane-Induced Peripheral Neuropathy},
journal = {JCO Precision Oncology},
year = {2025},
doi = {10.1200/po-24-00380}
}
EUVIMED